Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tezacitabine + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Tezacitabine + 5-fluorouracil is a combination of two **antineoplastic agents** investigated for the treatment of advanced solid tumors. **Tezacitabine** is a novel nucleoside analog that, after intracellular phosphorylation, inhibits ribonucleotide reductase and is incorporated into DNA, leading to DNA chain termination; it thereby disrupts DNA synthesis. **5-fluorouracil (5-FU)** is a pyrimidine analog that primarily inhibits thymidylate synthase, resulting in impaired DNA synthesis and repair, and is also incorporated into RNA and DNA, exerting cytotoxic effects. The combination was studied in solid tumors (including esophageal and gastrointestinal carcinomas), showing tolerability and preliminary antitumor activity in Phase I trials[1][3].
- Other names
- (E)-2'-deoxy-2'-(fluoromethylene) cytidine + 5-fluorouracil
02
Targets
RRM1TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on tezacitabine + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tezacitabine + 5-fluorouracil.